Last updated: March 2026
Dihexa (PNB-0408) is a synthetic hexapeptide HGF mimetic that activates the c-Met receptor pathway — the same system that drives synaptic formation in brain development. Animal studies show extraordinary in vitro potency. Zero human clinical trials. High-controversy, high-search-interest research compound.
Evidence Tier: Animal Only. Every Dihexa efficacy claim originates from rat studies and cell cultures. There are no published human clinical trials for Dihexa (PNB-0408) anywhere in the world. The "millions of times more potent than BDNF" figure is an in vitro binding affinity measurement — not a clinical potency comparison. Human pharmacokinetics, effective dosing, and long-term safety are completely unknown. This page presents what the animal literature shows — not a clinical endorsement.
Dihexa operates by mimicking hepatocyte growth factor (HGF) — a pleiotropic cytokine that activates the c-Met tyrosine kinase receptor. In the brain, HGF/c-Met signaling is a master regulator of synaptogenesis, neuronal survival, and synaptic plasticity.
Dihexa is a small hexapeptide derived from angiotensin IV (N-hexanoic-Tyr-Ile-[6]-aminohexanoic amide). It functions as a hepatocyte growth factor (HGF) mimetic — binding to c-Met (the HGF receptor) and activating downstream signaling cascades including PI3K/Akt and MAPK/ERK pathways. These pathways are central to neuronal survival, synapse formation, and long-term potentiation (LTP), the cellular basis of memory.
The c-Met pathway promotes synaptogenesis — the formation of new synaptic connections between neurons. Benoist et al. (2014) demonstrated that Dihexa increased spinophilin-immunoreactive puncta (a dendritic spine marker) in rat hippocampal tissue, consistent with increased synaptic density. HGF-driven synaptogenesis is particularly potent in hippocampal CA1 and CA3 regions critical for memory encoding. This is the proposed mechanism behind Dihexa's cognition-enhancing effects in animal models.
The "10 million times more potent than BDNF" figure comes from the EC50 for synaptogenesis in hippocampal slice cultures — Dihexa was active at ~1 nM versus BDNF at ~10 μM in the same assay. This is a relative binding/activation efficiency measure in isolated tissue, not a claim that Dihexa produces 10 million times more cognitive enhancement in humans. In vitro potency rarely translates linearly to clinical efficacy. BDNF is itself highly restricted in human therapeutic use; comparing EC50s doesn't predict human outcomes.
Unlike most peptides, Dihexa was engineered to resist rapid degradation and cross the blood-brain barrier. McCoy et al. (2010) demonstrated that Dihexa retained bioactivity after oral administration in rats and achieved CNS penetration — a significant property for a peptide. This distinguishes it from larger peptides (like cerebrolysin) that require intravenous or subcutaneous injection. However, human oral bioavailability data does not exist.
Dihexa was discovered in Dr. Joseph Harding's lab at Washington State University during research into angiotensin IV (Ang IV) — an active fragment of the renin-angiotensin system. Ang IV was found to have cognitive-enhancing properties mediated through an HGF-like mechanism. Dihexa is a synthetic analog optimized for stability and CNS penetration, stripping Ang IV's vasopressor activity while preserving the synaptogenic mechanism. This pharmaceutical design makes Dihexa conceptually distinct from other angiotensin peptides.
HGF/c-Met is a well-characterized oncogenic axis. Aberrant HGF/c-Met signaling drives tumor growth, angiogenesis, epithelial-mesenchymal transition (metastasis), and treatment resistance in gastric cancer, lung cancer, renal cell carcinoma, hepatocellular carcinoma, and glioblastoma. Multiple FDA-approved cancer drugs (capmatinib, tepotinib, crizotinib) are inhibitors of c-Met. Dihexa activates this axis — a meaningful oncogenic risk signal that has no published long-term data to either confirm or refute.
The entire Dihexa evidence base is preclinical. The primary research comes from Dr. Joseph Harding's lab at Washington State University — essentially a single research group. This is a meaningful limitation: findings have not been independently replicated in multiple labs with different animal models, which is standard preclinical validation before human trials. The studies are real, published, and peer-reviewed — but they represent early-stage data, not a clinical evidence base.
The most compelling indirect signal that HGF/c-Met activation may have therapeutic merit is the existence of pharmaceutical programs targeting the same pathway.
Fosgonimeton (ATH-1017) is a phosphate prodrug version of a Dihexa-related HGF/c-Met pathway activator. It was originally developed by Athira Pharma, which has since been rebranded as Quince Therapeutics. The compound converts to its active form in the body and targets the same c-Met mechanism as Dihexa, though as distinct molecules the two should not be conflated.
Phase 1: Fosgonimeton was well-tolerated in early-phase human testing and achieved target plasma concentrations, clearing the initial safety bar. This represented the first human pharmacokinetic data for the HGF/c-Met activator class.
Phase 2 — Mixed Picture: Phase 2 trials in Alzheimer's disease and Parkinson's disease dementia produced mixed results. Biomarker improvements appeared in subgroups of patients, but the primary cognitive endpoint did not reach statistical significance across the full study population. Quince Therapeutics is now refining patient selection criteria — looking for subgroups where the pathway activation is most likely to be clinically meaningful — ahead of future trials.
Interpretation: The Phase 2 stumble doesn't invalidate the mechanism — many drugs show subgroup signals before the field learns which patients actually respond. But it does temper the optimism that surrounded earlier Phase 1 results. The HGF/c-Met pathway remains a legitimate therapeutic target; translating that into consistent cognitive benefit in humans is proving harder than preclinical data suggested.
An important finding that often gets buried in the biohacker hype: animal research shows that Dihexa did not improve cognition in rats with normal cognitive function. The observed benefits — memory improvement, social recognition, maze performance — were specific to impairment models (such as scopolamine-induced deficits). Healthy-brain animals showed no measurable enhancement.
This positions Dihexa as a potential restorative agent in cognitive impairment — not a general enhancer for people with normal baseline cognition. If you're a healthy adult hoping for a cognitive edge, the animal data doesn't actually support that expectation. This distinction matters significantly for how Dihexa is being evaluated in clinical contexts.
| Feature | Dihexa (PNB-0408) | Fosgonimeton (ATH-1017) |
|---|---|---|
| Molecule type | Hexapeptide | Small molecule |
| Primary mechanism | HGF mimetic / c-Met activator | c-Met activator (allosteric) |
| Route (studied) | Oral (rats); intranasal (anecdotal) | Subcutaneous injection |
| Human trials | None published | Phase 2 (Alzheimer's, Parkinson's) |
| Regulatory status | Research chemical | IND (Investigational New Drug) |
| Safety data (humans) | None | Phase 2 cohort data available |
| Can extrapolate to other | NO — different molecules, different profiles | |
HGF/c-Met is an oncogenic pathway. This is not a theoretical or minor concern — it is a well-documented oncogenic signaling axis. Multiple FDA-approved cancer drugs are HGF/c-Met inhibitors (capmatinib, tepotinib, crizotinib). Dihexa activates this pathway. Anyone with a personal or family history of cancer, or high cancer risk factors, should treat this as a serious contraindication.
Aberrant HGF/c-Met signaling is implicated in gastric cancer (MET amplification), non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, and glioblastoma multiforme. The pathway drives tumor cell proliferation, survival, angiogenesis (blood supply to tumors), and invasion/metastasis. The FDA has approved c-Met inhibitors as cancer treatments precisely because this axis is so oncogenically potent.
The oncogenic risk from short-term HGF/c-Met activation at nootropic doses is entirely unknown. No animal carcinogenicity studies with Dihexa have been published. Standard drug development would require multi-year rodent carcinogenicity studies before human trials — these have not been conducted or published. The risk could be low, moderate, or high — there is simply no data.
Endogenous HGF/c-Met signaling occurs naturally in healthy brain development and injury repair. The concern is not that any c-Met activation causes cancer — it's that sustained, pharmacological upregulation of this axis beyond normal physiological ranges carries unknown long-term risk, particularly in peripheral tissues (liver, lung, kidney) where c-Met overactivation is clearly oncogenic.
Athira Pharma's fosgonimeton Phase 2 trials did not report significantly elevated cancer adverse events during the trial period. However, Phase 2 trials are short-term (months), use carefully selected patients, and are not designed to detect long-latency carcinogenesis. A clean short-term Phase 2 safety record does not rule out cancer risk with years of use — and again, fosgonimeton ≠ Dihexa.
The honest answer: Dihexa is a research compound for investigators who understand they are self-experimenting with a molecule that has zero human safety or efficacy data. It is not a safe nootropic. It is not a validated cognitive enhancer. It is a compound of theoretical interest derived from preclinical evidence that may or may not translate to humans. Anyone considering it must fully accept these conditions.
Supplements and tools for cognitive health and the serious nootropic researcher.
Affiliate links help support MeetPeptide at no extra cost to you.
Dihexa is NOT approved for human use anywhere in the world. It has never been studied in human clinical trials. This page is for educational and research purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The cancer risk section is not hypothetical — the HGF/c-Met pathway is a validated oncogenic axis. Do not use this information to make decisions about your health without consulting a qualified healthcare provider who understands the mechanism. Animal Data OnlyNo Human TrialsRelated Pathway: Phase 2